CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $833.19M, above the global median of $548.88M
- FinancialsAltman Z-Score 0.99: distress zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
381.58MUSDvs all stocks (USD)
Revenue (TTM)
833.19MUSDvs all stocks (USD)
Profit Margin
-7.41%vs Medical Devices peers
Beta
0.6460xvs all stocks
52-Week Change
-34.26%vs all stocks
Market Capitalization
381.58MUSDvs all stocks (USD)
Enterprise Value
542.61MUSDvs all stocks (USD)
Forward P/E
25.51xvs Medical Devices peers
Price to Sales (TTM)
0.4580xvs Medical Devices peers
Price to Book (MRQ)
0.8959xvs Medical Devices peers
Enterprise to Revenue
0.6510xvs Medical Devices peers
Enterprise to EBITDA
25.93xvs Medical Devices peers
Gross Margin
70.97%vs Medical Devices peers
Profit Margin
-7.41%vs Medical Devices peers
Operating Margin
-3.26%vs Medical Devices peers
Return on Assets (TTM)
-2.74%vs Medical Devices peers
Return on Equity (TTM)
-13.91%vs Medical Devices peers
Revenue (TTM)
833.19MUSDvs all stocks (USD)
Revenue per Share (TTM)
20.68USDUpdated Sep 28, 2026Quarterly Revenue Growth
3.80%vs Medical Devices peers
Gross Profit (TTM)
593.73MUSDvs all stocks (USD)
EBITDA (TTM)
8.79MUSDvs all stocks (USD)
Net Income (TTM)
-61.72MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
3.85%vs Medical Devices peers
Operating Cash Flow (TTM)
16.27MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
4.10MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
822.31MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
256.30MUSDFY2025 · Dec 31, 2025Gross Profit
566.02MUSDFY2025 · Dec 31, 2025Operating Income
-82.57MUSDvs all stocks (USD)
Pre-tax Income
-90.81MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.38MUSDFY2025 · Dec 31, 2025Net Income
-92.19MUSDFY2025 · Dec 31, 2025EBIT
-73.32MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
8.79MUSDFY2025 · Dec 31, 2025Research & Development
65.85MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
554.33MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
17.49MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.33USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.33USDFY2025 · Dec 31, 2025Basic Shares Outstanding
39.60MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
39.60MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-92.19MUSDFY2025 · Dec 31, 2025Operating Cash Flow
3.05MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
85.11MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-92.19MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
83.25MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
223.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
28.69MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-690.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.58MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.60MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.25MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Other Investing Activity
28.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
28.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-762.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-5.95MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-786.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
40.73MSharesUpdated Sep 28, 2026Float Shares
40.41MSharesUpdated Sep 28, 2026Shares Short
2.51MSharesUpdated Sep 28, 2026Short Ratio
8.16daysvs all stocks
Short % of Shares Outstanding
6.95%vs all stocks
% Held by Insiders
2.17%vs all stocks
% Held by Institutions
95.97%vs all stocks
Total Cash (MRQ)
103.81MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.55USDUpdated Sep 28, 2026Total Debt (MRQ)
261.90MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6102xvs Medical Devices peers
Current Ratio (MRQ)
2.84xvs Medical Devices peers
Book Value per Share (MRQ)
10.54USDUpdated Sep 28, 2026Total Assets
850.65MUSDvs all stocks (USD)
Total Current Assets
416.85MUSDFY2025 · Dec 31, 2025Total Liabilities
400.61MUSDFY2025 · Dec 31, 2025Total Non-current Assets
433.80MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
230.13MUSDFY2025 · Dec 31, 2025Total Current Liabilities
170.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
82.03MUSDFY2025 · Dec 31, 2025Accounts Receivable
135.75MUSDFY2025 · Dec 31, 2025Inventory
172.32MUSDFY2025 · Dec 31, 2025Accounts Payable
58.39MUSDFY2025 · Dec 31, 2025Short-term Debt
3.98MUSDFY2025 · Dec 31, 2025Other Current Liabilities
4.29MUSDFY2025 · Dec 31, 2025Long-term Debt
174.45MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
55.68MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.98MUSDFY2025 · Dec 31, 2025Retained Earnings
-368.33MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
450.04MUSDvs all stocks (USD)
52-Week Low
8.50USDUpdated Sep 28, 202652-Week High
16.99USDUpdated Sep 28, 202652-Week Change
-34.26%vs all stocks
Beta
0.6460xvs all stocks
50-Day MA
10.14USDUpdated Sep 28, 2026200-Day MA
11.83USDUpdated Sep 28, 2026Avg 10-Day Volume
407.39KSharesUpdated Sep 28, 2026Avg 30-Day Volume
340.39KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.52USDUpdated Sep 28, 2026Other Income / Expense
9.25MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Diagnostic
Earnings Growth With Heavy Accrual Component
It reports a profit, with depreciation heavy in the cash bridge and receivables rising.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.71Profit Margin: -0.07
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.84Altman Z-Score: 0.99
Financial Health
Altman Z-Score 0.99: distress zoneCritical
Altman Z-Score: 0.99
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $833.19M, above the global median of $548.88MNotable
Revenue (USD): 833,185,984Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
G2GBio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kontour Xi'an Medical Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Alignment Healthcare, Inc.
3 interpretationsRevenue Growing With Receivables GrowingEarnings Growth With Heavy Accrual ComponentDepreciation-Heavy Reported Profit
Certara, Inc.
3 interpretationsRevenue Growing With Receivables GrowingEarnings Growth With Heavy Accrual ComponentDepreciation-Heavy Reported Profit
Netflix, Inc.
2 interpretationsEarnings Growth With Heavy Accrual ComponentDepreciation-Heavy Reported Profit